XNYS · Medical Devices
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$44.70+1.54%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
58/100
Positive
Score components
TickerWhale View
Boston Scientific scores 58 out of 100 overall, which we rate positive. Valuation is its strongest area and Technical its weakest.
What helps
- Quality & growth
- Valuation
What to watch
- Technical
- Risk
- Sentiment Signal
Quality & growth
30%83Strong
- Revenue growth 13.5%
- EPS growth 47.0%
Valuation
25%90Strong
- P/E 17.9
- EV/Sales 3.7
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
#205 by market cap in our coverage · ~59,000 employees · Listed 1992-05-18 · www.bostonscientific.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#56 / 139sector rank by TickerWhale Score
TickerWhale Score 58 vs sector average 54.6 (+3.4)
Revenue growth (industry)Top 44%
Gross margin (industry)Top 22%
Return on equity (industry)Top 28%
P/E (industry)Cheaper than 100%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
17/100Weak vs universe
Ranks 17th of 100 covered names on our technical composite — the composite itself scores 28/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 1 sell · 4 neutral of 8 votes
TickerWhale rates BSX's technical setup weak — 17th percentile of the covered universe. Classic chart indicators lean buy — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
5 / 9constructive
- vs 200-day-18.5%
- vs 50-day+1.1%
Momentum
Mixed
- RSI (14)52 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength18· weak trend
- MACD (12,26,9)buy(histogram 0.052)
How the classic verdict is reached
Moving averages (9) agree on buy — 5 buy vs 3 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 1 sell · 4 neutral.
Result — 3 buy vs 1 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)17.9
- P/S (TTM)3.1
- P/B2.6
- EV/EBITDA—
- EV/Sales3.7
- PEG0.38
Profitability & returns
- Gross margin69.9%
- Net margin17.5%
- ROE14.5%
- Debt/Equity0.51
Growth
- Revenue growth (YoY)13.5%
- EPS growth (YoY)47.0%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $65.9B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $20.1B | $16.7B | $14.2B |
| Gross profit | $13.9B | $11.5B | $9.9B |
| Operating income | $3.6B | $2.6B | $2.3B |
| Net income | $2.9B | $1.9B | $1.6B |
| EPS (diluted) | $1.94 | $1.25 | $1.07 |
| Free cash flow | $3.7B | $2.6B | $1.8B |
| Cash | $2.0B | $414M | $865M |
| Total debt | $11.4B | $10.7B | $9.1B |
| Equity | $24.2B | $21.8B | $19.3B |
| Net debt | $9.5B | $10.3B | $8.2B |
| Debt / equity | 0.47 | 0.49 | 0.47 |
| Liabilities / assets | 0.44 | 0.44 | 0.44 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BSXCurrentBoston Scientific | 58 | 28 | 17.9 | — | 2.6 | 3.7 | $44.70 | +1.54% | +13.5% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.